as 11-06-2025 3:56pm EST
Stocks
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 33.4M | IPO Year: | 2024 |
| Target Price: | $4.00 | AVG Volume (30 days): | 143.3K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.76 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.00 - $3.75 | Next Earning Date: | 11-05-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
BOLD Breaking Stock News: Dive into BOLD Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
GlobeNewswire
24 days ago
GlobeNewswire
5 months ago
MT Newswires
5 months ago
GlobeNewswire
5 months ago
Zacks
6 months ago
GlobeNewswire
6 months ago
GlobeNewswire
7 months ago
The information presented on this page, "BOLD Boundless Bio Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.